Capturing Amyloid-β Oligomers by Stirring with Microscaled Iron Oxide Stir Bars into Magnetic Plaques to Reduce Cytotoxicity toward Neuronal Cells

Yuan-Chung Tsai, Jing-Chian Luo, Te-I Liu, I-Lin Lu, Ming-Yin Shen, Chun-Yu Chuang, Chorng-Shyan Chern and Hsin-Cheng Chiu

1 Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan; smallqq_109@hotmail.com (Y.-C.T.); eric820713@hotmail.com (J.-C.L.); be0007599@gmail.com (T.-I.L.); b8201130@yahoo.com.tw (I.-L.L.); mingyin.shen@gmail.com (M.-Y.S.); cychuang@mx.nthu.edu.tw (C.-Y.C.)

2 Department of Surgery, Hsinchu Mackay Memorial Hospital, Hsinchu 30071, Taiwan

3 Department of Surgery, China Medical University Hospital-Hsinchu Branch, Hsinchu 30059, Taiwan

4 Department of Chemical Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan; cschern@mail.ntust.edu.tw

* Correspondence: hschihui@mx.nthu.edu.tw; Tel.: +886-3-5715131 (ext. 34233)

Received: 29 April 2020; Accepted: 28 June 2020; Published: 30 June 2020

Abstract: Soluble amyloid-β oligomers (oAβ42)-induced neuronal death and inflammation response has been recognized as one of the major causes of Alzheimer’s disease (AD). In this work, a novel strategy adopting silica-coated iron oxide stir bar (MSB)-based AD therapy system via magnetic stirring-induced capture of oAβ42 into magnetic plaques (mpAβ42) and activation of microglia on cellular plaque clearance was developed. With oAβ42 being effectively converted into mpAβ42, the neurotoxicity toward neuronal cells was thus greatly reduced. In addition to the good preservation of neurite outgrowth through the diminished uptake of oAβ42, neurons treated with oAβ42 under magnetic stirring also exhibited comparable neuron-specific protein expression to those in the absence of oAβ42. The phagocytic uptake of mpAβ42 by microglia was enhanced significantly as compared to the counterpart of oAβ42, and the M1 polarization of microglia often occurring after the uptake of oAβ42 restricted to an appreciable extent. As a result, the inflammation induced by pro-inflammatory cytokines was greatly alleviated.

Keywords: Alzheimer’s disease; amyloid beta-peptides; microglial cell polarization; microscaled stirring; magnetic stir bars

1. Introduction

The abnormal accumulation of amyloid-β oligomers (oAβ42) and protofibrils within neuronal/microglial cells is believed to be crucial to Alzheimer’s disease (AD) progression [1]. Although new strategies in therapeutic regimens including β-secretase 1 (BACE1) inhibition, γ-secretase suppression, and passive anti-amyloid-β immunotherapies [2,3] have been proposed, the efficacy is still not significant probably due to the incomplete elimination of oAβ42 species in brain. For instance, an oral BACE1 inhibitor, Lanabecestat, was discontinued in phase III clinical study owing to its insignificant therapeutic efficacy [4]. A passive anti-amyloid-β antibody drug, solanezumab, was failed in clinical trial due to the poor improvement on cognitive impairment [5]. In addition to the neurotoxicity of oAβ42 from the impairment of synaptic plasticity in association with the interaction of oAβ42 with cellular prion protein [6,7], oAβ42 may further induce microglial cell polarization into M1 phenotype along with severe phagocytic function attenuation toward toxic species [8,9]. Moreover, the neuroinflammation
induced by pro-inflammatory cytokines released from M1 type microglial cells further enhances the apoptosis of neuronal cells [10–12]. By contrast, the M2 phenotype microglial cells exhibit a superior phagocytic capability to eliminate Aβ_{42} in comparison with other resident central nervous system (CNS) immune cells such as M1 type microglial cells, astrocytes, and possibly neuronal cells [13–15]. Furthermore, the secretion of neurotrophic factors and anti-inflammatory cytokines from M2 microglial cells in brain regions helps repair CNS damage and alleviate inflammation [16]. Unfortunately, naive microglial cells localized in neuroinflammatory regions are apt to differentiate into the M1 phenotype, which further deteriorates inflammatory conditions [17,18].

It has been reported that sulindac sulfide and orcein-related drug (O) can be employed as stimulators for accelerating the aggregation of oAβ_{42}, which reduce its neurotoxicity for effective AD treatment [19,20]. On the other hand, β-secretase 1 (BACE) inhibitor was found capable of reducing soluble form of Aβ_{42} (oAβ_{42}) accompanied by rescue of cognitive dysfunction and memory deficits in a mouse model of AD [21]. Similarly, Meier et al. employed a BACE inhibitor (NB-360) to serve as a scavenger for Aβ reduction in tg-ArcSwe mice [22]. Nevertheless, these approaches are somewhat limited due to the ineffective elimination of oAβ_{42}.

This work was aimed to develop a novel therapeutic strategy to achieve rapid capture and subsequent removal of oAβ_{42} and prevention of neuroinflammation for potential AD treatment. Distinct from small molecule drugs as aforementioned that require a slow progression process involved in the oAβ_{42} aggregation, a MSB-based approach was developed and characterized in relation with the capability to effectively capture oAβ_{42} into mpAβ_{42} by facile magnetic stirring. The MSBs comprising aligned superparamagnetic iron oxide nanoparticles (SPIONs) coated by silica in rod shape were prepared and characterized with respect to the morphology by scanning electron microscopic (SEM) examination and the stirring effect under rotating magnetic field. The therapeutic effect on neuron cells by rapid capture of oAβ_{42} with the aid of MSBs under magnetic stirring into mpAβ_{42} in terms of cell viability and morphology, neuron-specific protein expression, and oAβ_{42}-induced neuron membrane damage was extensively examined. A reduction in the uptake of oAβ_{42} by microglial cells also leads to a significant decrease in polarization of microglial cells into the M1 type. This will then greatly reduce the level of the pro-inflammatory cytokines. The internalization efficiency of oAβ_{42} and mpAβ_{42} by microglial cells and the effect on cell polarization was thus investigated. The in vivo biocompatibility of the MSB-based therapeutic system with stirring in terms of brain tissue damage from C57BL/6 mice was examined by the immunohistochemistry (IHC) staining. To the best of our knowledge, this is the first study demonstrating the rapid capture of oAβ_{42} by MSB under magnetic stirring and its potential for AD treatment. The therapeutic strategy developed herein is illustrated schematically in Figure 1.
Figure 1. Illustration of the effective therapeutic action by capture of $\alpha A\beta_{42}$ species into magnetic plaques and enhanced cellular clearance by the M2 type microglial cells for AD treatment.

2. Materials and Methods

2.1. Reagents and Materials

Preparation of oleic acid coated SPIONs (OA-SPIONs) was conducted as reported previously [23]. Congo red (CR), thioflavin T (ThT), and hematoxylin and eosin (H&E) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Tetraethyl orthosilicate (TEOS) and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) were acquired from Alfa Aesar (Haverhill, MA, USA). $A\beta_{42}$ peptide (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) was acquired from Chinapeptide (Shanghai, China). Lactate dehydrogenase (LDH) assay kit, Hoechst 33342, rabbit anti-oligomer (A11) polyclonal antibody (AHB0052) and goat anti-mouse IgG secondary antibody (Alexa Fluor 568) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Anti-mouse F-actin antibody, goat anti-mouse IgG secondary antibody (Alexa Fluor 488), and donkey anti-rabbit IgG secondary antibody (Alexa Fluor 594) were obtained from Abcam (Cambridge, UK). Microtubule-associated protein 2 (MAP2) antibody and anti-human $\beta$-amyloid (6E10) antibody were purchased from BioLegend (San Diego, CA, USA). Neuronal nuclei (NeuN) antibody and neurofilament M (NF-M) antibody were supplied by Merck (Darmstadt, Germany). 4',6-Diamidino-2-phenylindole (DAPI), singlet oxygen sensor green (SOSG) reagent and anti-mouse caspase-3 antibody were purchased by Invitrogen (Eugene, OR, USA). N2a (murine neuroblastoma cells) and BV-2 (murine microglial cells) were obtained from...
Food Industry Research and Development Institute (Hsinchu City, Taiwan). C57BL/6J male mice were purchased from the National Laboratory Animal Center, Taiwan. Approved guidelines for the care and use of laboratory animals by the Institutional Animal Care and Use Committee (IACUC: 10129) were followed.

2.2. Preparation and Characterization of MSBs

The lauric acid/oleic acid coated SPIONs (LA/OA-SPIONs) were prepared using the oil-in-water emulsion technique. LA sodium salt (200 mg in 15 mL deionized water) and OA-SPIONs (15 mg in 200 µL chloroform) were mixed by ultrasonication for 10 min in an ice–water bath. This was followed by removal of chloroform by rotary evaporation. The resultant LA/OA-SPIONs were well dispersed in deionized water and phosphate buffered saline (PBS). The mean hydrodynamic diameters ($D_h$), size distributions (polydispersity index, PDI), and zeta potentials of OA- and LA/OA-SPIONs in n-hexane and PBS, respectively, were determined by dynamic light scattering (DLS, ZetaSizer Nano Series, Malvern, UK). Preparation of MSBs was carried out according to the method previously reported [24]. The MSBs in microscale were prepared according to the method reported previously by neodymium magnet assisted alignment of SPIONs into rod-shaped structure in aqueous phase while the SPION surfaces were concomitantly coated with TEOS-based silica to maintain the desired particle morphology and improve the colloidal stability. In brief, LA/OA-SPIONs (0.05 mg) were dispersed in a mixture of isopropanol (1 mL) and deionized water (600 µL) under sonication. A NH$_4$OH solution (28%, 20 µL) and TEOS (20 µL) was added in sequence into the aqueous suspension of LA/OA-SPIONs and the reaction solution was then placed between two 10 × 20 × 30 mm neodymium magnets (4100 gauss) at a distance of 1.0 cm for 20 min at room temperature. After removal from the magnetic field, the sample was purified through centrifugation (1,900 g, 2 min) with deionized water three times and re-dispersed in deionized water. The morphology of SPIONs and MSBs was examined by transmission electron microscope (TEM) (T7700, Hitachi, Tokyo, Japan). SEM examination was conducted on a Hitachi S-4700 field emission microscope. Characterization of superparamagnetic properties was carried out on a superconducting quantum interference device (SQUID) magnetometer at 300 K (MPMS-XL Quantum Design, San Diego, CA, USA). The Fe content of OA-SPIONs was determined by thermogravimetric analyzer (TGA, Mettler-Toledo, Greifensee, Switzerland) at a heating rate of 10 °C min$^{-1}$. X-ray diffraction (XRD) measurements of OA-SPIONs and LA/OA-SPIONs were conducted on a TTRax III diffractometer (Rigaku, Japan).

2.3. Preparation and Characterization of oAβ$_{42}$ and Natural Aβ$_{42}$ Plaques (npAβ$_{42}$)

oAβ$_{42}$ and npAβ$_{42}$ were prepared and characterized according to the methods described previously [25–28]. The Aβ$_{42}$ peptide was initially dissolved in HFIP (1.0 mM) and the solution was divided into aliquotes in sterile microcentrifuge tubes. HFIP was then removed under vacuum. The peptide film thus obtained was stored in dessicator at −20 °C before use. The β-sheet motif of npAβ$_{42}$ was examined by ThT assay and CR spectroscopic analysis. For ThT assay, Aβ$_{42}$ in dimethyl sulphoxide (DMSO) was added with 100 µL PBS (pH 7.4, ionic strength 0.15 M) to a concentration of 20 µM in 96-well plates. ThT was added (10 µM) and the solution was incubated at 37 °C as a function of time. The fluorescence intensity of ThT was determined by a microplate reader (Infinite M200 PRO, Männedorf, Switzerland). The excitation was performed at 442 nm and the emission spectrum was recorded in the range of 445–482 nm. The characteristic absorbance of CR at 490 nm and the red shift in the CR absorption band with the occurrence of npAβ$_{42}$ in the range of 490–540 nm was determined using a UV–vis spectrophotometer. For the 100 µM oAβ$_{42}$ preparation, the Aβ$_{42}$ peptide film was first dissolved in dry DMSO to a concentration of 5 mM. The solution was then diluted with the Dulbecco’s Modified Eagle’s Medium (DMEM) (phenol red-free) to an Aβ$_{42}$ concentration of 100 µM. The solution was further incubated at 4 °C for 24 h. The morphology of oAβ$_{42}$ and npAβ$_{42}$ was examined by transmission electron microscopy (TEM, HT7700, Hitachi, Tokyo, Japan). Briefly, the Aβ dispersion was dropped onto a carbon-coated copper grid (200 mesh copper grids, Ted Pella, Inc., Redding, CA,
USA) and stained with 1 wt % uranyl acetate solution for 1 min and dried at 25 °C for 2 days before measurements. The stained samples were analyzed by TEM operating at an accelerating voltage of 100 kV.

2.4. In Vitro Stirring-Induced oAβ42 Capture

The capture effect of the magnetic stirring treatment with MSBs on oAβ42 species of varying concentrations (0.3–160 µM) under rotating magnetic field at 2500 rpm was determined by fluorescence microscope (Olympus IX70, Tokyo, Japan). Rotating magnetic stirring was conducted on an IKA magnetic stirrer (color squid, Staufen, Germany) with a dynamic magnetic attraction force in the range 15–30 mT. The stirring speed was calibrated with an external speed sensor, which reacts to magnetic impulses. The power consumption is 3 W and the motor rating output is 2 W. For the preparation of 20 µM oAβ42, the peptide film prepared previously was dissolved in dry DMSO to a concentration of 5 mM. The solution was then diluted with the DMEM medium (phenol red-free) to an Aβ42 concentration of 20 µM, followed by re-incubation at 4 °C for 24 h. The oAβ42 (20 µM) was first treated with magnetic stirring as a function of the concentration of MSBs at 2500 rpm for 20 min. The Aβ42 was then stained with 10 µM ThT (λex = 442 nm, λem = 445–482 nm) and CR (λex = 497 nm, λem = 596–632 nm) dyes. The total and mean areas of the stained mpAβ42 were quantified with the functions of Image-Pro Plus 6.0 (n = 10). The morphology of mpAβ42 was examined by TEM, scanning probe microscopy (SPM, tapping mode, Bruker, Model-Dimension Icon, Camarillo, CA, USA) and atomic force microscope (AFM, Bruker, Santa Barbara, CA, USA) [29–32].

2.5. Cell Membrane Damage and Neurite Outgrowth Impairment

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and trypan blue assays were used to determine the cell viability of N2a cells co-incubated with oAβ42 species (160 µM) under the MSB stirring treatment (2500 rpm, 2 h). For 160 µM oAβ42 preparation, the peptide film obtained previously was dissolved in dry DMSO to a concentration of 5 mM. The solution was then diluted with the DMEM medium (phenol red-free) to a concentration of 5 mM. The solution was then diluted with the DMEM medium (phenol red-free) to an Aβ42 concentration of 20 µM, followed by re-incubation at 4 °C for 24 h. The oAβ42 (20 µM) was first treated with magnetic stirring as a function of the concentration of MSBs at 2500 rpm for 20 min. The Aβ42 was then stained with 10 µM ThT (λex = 442 nm, λem = 445–482 nm) and CR (λex = 497 nm, λem = 596–632 nm) dyes. The total and mean areas of the stained mpAβ42 were quantified with the functions of Image-Pro Plus 6.0 (n = 10). The morphology of mpAβ42 was examined by TEM, scanning probe microscopy (SPM, tapping mode, Bruker, Model-Dimension Icon, Camarillo, CA, USA) and atomic force microscope (AFM, Bruker, Santa Barbara, CA, USA) [29–32].
2.6. Cell Functions

The cellular functions in terms of specific protein expression were examined by western blotting. Proteins were subjected to a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF) membrane. The PVDF membrane was blocked using 5% nonfat milk blocking buffer with anti-MAP-2, NF-M, and NeuN primary antibody at 4 °C for 24 h. It was then incubated at 37 °C for 1 h with horse radish peroxidase-conjugated secondary antibody. β-Actin was used as the loading control. The area and signal intensity of the detected bands were determined using the Molecular Imager PhorosFX Plus System and quantified using the ImageJ software (v1.33, National Institute of Mental Health, MD, USA).

2.7. Phagocytic Activity of Microglial Cells

BV-2 cells were adopted as a microglia cell model for evaluating the uptake of Aβ42 in different forms (i.e., oAβ42, npAβ42 and mpAβ42). BV-2 cells (3 × 10^5 cells per well) were seeded on glass coverslips and cultured at 37 °C under 5% CO2/air overnight. This was followed by co-incubation with the Aβ42 species at varying concentrations. With 6 h co-incubation, the coverslips were washed with PBS twice, fixed with 4% paraformaldehyde and stained with 6E10 for 10 min in sequence. The extent of cellular uptake of Aβ42 in different forms by microglia was visualized at the excitation and emission wavelengths of 488 nm and 590 nm, respectively, with LSCM.

2.8. Cytokine Production

Levels of IL-1β, TNF-α and IL-10 released from BV-2 cells after uptake of Aβ42 species of various structures were examined by enzyme-linked immunosorbent assay (ELISA). A 96-well tailor-made mouse multi-analyte ELISArray kit (Qiagen, SA Biosciences, Hilden, UK) was employed to determine the concentrations of TNF-α, IL-1β, and IL-10 in the collected culture media according to the manufacturer’s instruction.

2.9. Brain Tissue Toxicity and Damage with MSB Stirring

The intracranial injection of 2 μL of the aqueous MSB dispersion (0.5 and 1.0 μg in 2 mL of F-12K medium, respectively) into the hippocampus area of healthy C57BL/6J mice with the magnetic stirring was conducted in this work to evaluate the in vivo brain tissue toxicity and damage by MSB stirring [34–36]. In brief, male C57BL/6J mice (6–8 weeks old) were first anesthetized with Zoletil-Rompun by intraperitoneal injection and placed in an animal stereotaxic apparatus (Stoelting, Wood Dale, IL, USA). Two μL of the aqueous MSB dispersion were injected intracranially into the hippocampus area using a 10 μL Hamilton syringe equipped on the stereotoxic instrument with a 27-gauge needle and a microinjection auto-pump (KD Scientific, Hollison, MA, USA). After the needle was gently withdrawn, the burr hole was immediately sealed with bone wax and the surgical incision was sutured. This was followed by magnetic stirring (2400 rpm) over 20 min. At the prescribed time points, the brains were isolated and sectioned. The reactive oxygen species (ROS) level induced from Fe^{2+} and Fe^{3+} ions (Fenton reaction) with the dissolution of MSBs was determined by SOSG. The cell
apoptosis in brain tissue sections was examined by caspase 3 IHC staining. The Prussian blue staining was used to determine the Fe content in brain tissue with time. The hippocampus tissue sections were H&E stained for histologic examination under optical microscopy.

2.10. Statistical Analysis

All experiments were performed at least in triplicate and data were reported as mean ± standard deviation. Statistical significance was determined using one-way ANOVA and Bonferroni post-hoc test. Significant differences were defined as (*) \( p < 0.05 \), (**) \( p < 0.01 \), and (***) \( p < 0.005 \). Not significant differences were displayed as N.S. \( (p > 0.05) \).

3. Results and Discussion

3.1. Preparation and Characterization of MSBs

The MSBs in microscale were prepared according to the method reported previously [24]. Through the neodymium magnet assisted alignment of SPIONs into rod-shaped structure in aqueous phase, the SPION surfaces were concomitantly coated with TEOS-based silica to maintain the desired particle morphology and improve the colloidal stability. The particle surface of SPIONs in the form of OA-SPIONs prepared by the thermal decomposition technique were modified with LA by hydrophobic association to improve the aqueous colloidal dispersion. The results obtained from characterization of OA-SPIONs and LA/OA-SPIONs by TEM, TGA, SQUID, and XRD are shown in Figure S1. TEM images of LA/OA-SPIONs and OA-SPIONs confirm their spherical particle morphology. The resultant LA/OA-SPIONs still retain excellent superparamagnetic behavior with similar hysteresis to OA-SPIONs (Figure S1d). In addition, the XRD patterns of OA-SPIONs and LA/OA-SPIONs show high crystallinity in the spherical phase structure of \( \text{Fe}_3\text{O}_4 \) (JCPDS: 65-3107) (Figure S1e). Table S1 also shows the mean hydrodynamic diameters of OA-SPIONs in n-hexane and LA/OA-SPIONs in PBS and the zeta potential of LA/OA-SPIONs at pH 7.4. The optical microscopic, SEM, TEM, and high resolution TEM (HR-TEM) images of the MSBs developed herein are shown in Figure 2. The dimensions of MSBs were ca. 2.9 ± 0.7 \( \mu \)m in length and 132.4 ± 4.1 nm in diameter with the thickness of silica coating at ca. 45.5 ± 5.2 nm estimated by TEM image. The HR-TEM image further confirms the confinement of LA/OA-SPIONs in a relatively linear architecture within the silica coat (Figure 2d).

In the absence of magnetic field, MSBs remained as rod-like particles randomly dispersed in the continuous aqueous phase, as illustrated in Figure S2a. By contrast, MSBs became uniformly aligned in response to the direction of the applied external magnetic field (Figure S2b). The stirring effect of MSBs was observed by the accelerated dispersion of rhodamine B employed as a fluorescence dye in a water droplet in the presence of MSBs under an external magnetic rotating field (Figure S2c). Without magnetic stirring, the dye species resided locally within the water droplet. On the contrary, the dye species subjected to magnetic stirring became rapidly dispersed in the droplet and the extent of dispersion was dependent on the stirring speed and duration. Notably, a homogenous aqueous solution of rhodamine B was achieved over 20 s of stirring at 2500 rpm. The rapid rotation of MSBs is illustrated in Video S1, in which individual rotations of MSBs at various stirring speeds were recorded. The blinking phenomenon caused by light scattering during magnetic stirring was also observed (Video S2), similar to what has been reported elsewhere [37]. The colloidal stability of MSBs in different aqueous milieu was also evaluated in terms of the time-evolved change of light scattering intensity by DLS measurements. Figure S3 illustrates negligible variations in count rate of the aqueous MSB dispersions over a period of 1 h, indicating excellent colloidal stability under 500; 1500; or 2500 rpm magnetic stirring. Similar observation from the silica-coated nanoparticles was reported in the literature [38]. Being quite similar in surface modification, silica coating exhibited a strong resistance against both salt-induced aggregation in PBS and protein adsorption-evolved coagulation in Dulbecco’s modified Eagle medium (DMEM) solution primarily because of the high negative surface charge density of MSBs (\( \zeta \)-potential of ca. −35 mV).
afm techniques (Figure 4). the TEM images clearly demonstrate the agglutination of oA being treated with magnetic stirring (Figure 3). the signal areas of both ThT and CR in the aqueous oAβ_{42} solution subjected to magnetic stirring treatment increase dramatically compared to those without magnetic stirring treatment. these signals were observed obviously owing to the formation of oAβ_{42} aggregates. the total areas detected are in the range \(2 \times 10^5 - 3 \times 10^5 \, \mu m^2\) while the mean areas in the range 110–130 \(\mu m^2\) with oAβ_{42} being treated with magnetic stirring (Figure 3). The signal areas from ThT and CR overlapped mostly, indicating that both staining occurred at the same places. At constant stirring speed (2500 rpm), a rather weak dependence of the total signal area of the ThT/CR stained Aβ_{42} aggregates on the concentration of MSB in the range 144–576 \(\mu g/mL\) employed herein was observed. The effect of the MSB concentration (144–576 \(\mu g/mL\)) on the mean signal area (i.e., the oAβ_{42} aggregate size) is also essentially insignificant. In contrast to the magnetic stirring effect, the fluorescence signals of both ThT and CR were barely detected from the aqueous solution of oAβ_{42} without stirring over a period of 20 min. This result strongly suggests that the oAβ_{42} aggregate formation is substantially promoted by the magnetic stirring provided by MSBs as compared to the counterpart that is not subjected to stirring. It is noteworthy that the sound capture of oAβ_{42} is successfully achieved by magnetic stirring even at a concentration of 0.3 \(\mu M\). This implies the potential of the magnetic stirring with MSBs in practical applications for AD treatment (Figure S4).

The capture of oAβ_{42} into mpAβ_{42} via magnetic stirring with MSBs was further supported by comparison of the oAβ_{42} images before and after the magnetic stirring treatment using the TEM and AFM techniques (Figure 4). The TEM images clearly demonstrate the agglutination of oAβ_{42} after the magnetic stirring with MSBs while the small oAβ_{42} species were well separated from MSBs in the absence of the magnetic stirring treatment (Figure 4a). Both the 2-D and 3-D AFM topographic maps also corroborate the oAβ_{42} plaque formation promoted by MSB stirring with the plaque size being enormously enlarged in comparison with the oligomers (Figure 4b).

3.2. Capture Efficiency of Aβ_{42} by Magnetic Stirring of MSBs and In Vitro Therapeutic Efficacy

Rapid agglutination and capture of oAβ_{42} into mpAβ_{42} in cell culture medium by means of magnetic stirring with MSBs was studied first by fluorescence microscopy. As shown by the fluorescence images in Figure 3, the signal areas of both ThT and CR in the aqueous oAβ_{42} solution subjected to magnetic stirring treatment increase dramatically compared to those without magnetic stirring treatment. These signals were observed obviously owing to the formation of oAβ_{42} aggregates. The total areas detected are in the range \(2 \times 10^5 - 3 \times 10^5 \, \mu m^2\) while the mean areas in the range 110–130 \(\mu m^2\) with oAβ_{42} being treated with magnetic stirring (Figure 3). The signal areas from ThT and CR overlapped mostly, indicating that both staining occurred at the same places. At constant stirring speed (2500 rpm), a rather weak dependence of the total signal area of the ThT/CR stained Aβ_{42} aggregates on the concentration of MSB in the range 144–576 \(\mu g/mL\) employed herein was observed. The effect of the MSB concentration (144–576 \(\mu g/mL\)) on the mean signal area (i.e., the oAβ_{42} aggregate size) is also essentially insignificant. In contrast to the magnetic stirring effect, the fluorescence signals of both ThT and CR were barely detected from the aqueous solution of oAβ_{42} without stirring over a period of 20 min. This result strongly suggests that the oAβ_{42} aggregate formation is substantially promoted by the magnetic stirring provided by MSBs as compared to the counterpart that is not subjected to stirring. It is noteworthy that the sound capture of oAβ_{42} is successfully achieved by magnetic stirring even at a concentration of 0.3 \(\mu M\). This implies the potential of the magnetic stirring with MSBs in practical applications for AD treatment (Figure S4).

The capture of oAβ_{42} into mpAβ_{42} via magnetic stirring with MSBs was further supported by comparison of the oAβ_{42} images before and after the magnetic stirring treatment using the TEM and AFM techniques (Figure 4). The TEM images clearly demonstrate the agglutination of oAβ_{42} after the magnetic stirring with MSBs while the small oAβ_{42} species were well separated from MSBs in the absence of the magnetic stirring treatment (Figure 4a). Both the 2-D and 3-D AFM topographic maps also corroborate the oAβ_{42} plaque formation promoted by MSB stirring with the plaque size being enormously enlarged in comparison with the oligomers (Figure 4b).
Figure 3. Capture of oAβ42 into mpAβ42 by magnetic stirring with MSBs. (a) Fluorescence images of oAβ42 (20 μM) treated with magnetic stirring as a function of the concentration of MSBs at 2500 rpm for 20 min (n = 10). Scale bar: 100 μm. (b) The total and mean signal areas detected from the Aβ42 aggregation induced by magnetic stirring with MSBs were included. *** p < 0.005 and N.S. p > 0.05. Error bars represent mean ± s.d. (n = 10).

Figure 4. Structural analyses of oAβ42 and mpAβ42 by TEM and AFM. (a) TEM images of effective capture of oAβ42 into mpAβ42 via magnetic stirring. Scale bar: 2 μm. (b) Examination of mpAβ42 by AFM. 2D topographic images of oAβ42, oAβ42 + MSBs (0 rpm), and oAβ42 + MSBs (2500 rpm); and 3D topographic representations of oAβ42, oAβ42 + MSBs (0 rpm), and oAβ42 + MSBs (2500 rpm).
With mpAβ without the treatment. Apparently, the cytotoxicity of oAβ without the stirring treatment, the cell viability was significantly reduced compared to the cell only µ (0; 500; 1500; and 2500 rpm) and the concentration of MSB (up to 144 µg/mL) in PBS at 37 °C under mild shaking over 7 days. TEM images show that npAββ fully comprises fibrils while the aggregate size (ca. 70 µm² attained from the fluorescence microscopic examination) is somewhat smaller than that of mpAββ (ca. 125 µm²). It is interesting to note that the ThT fluorescence intensity reaches a plateau value of ca. 35,000 (a.u.) for the npAββ formation compared to ca. 20,000 for ThT with mpAββ at the same concentration of Aβ42 (20 µM) and ca. 1000 for ThT alone in aqueous solution. Comparing the structures of npAββ and oAββ shown by TEM images, obviously oAββ species are rather void of the fibril structure (Figure S5c), which by contrast predominates in npAββ (Figure S5d). With mpAββ being formed via the rapid capture of oAββ with the MSB stirring treatment, a decrease in the fluorescence intensity of ThT when bound with mpAββ in comparison with the signal intensity associated with the npAββ formation can thus be expected. Since the size of npAββ is smaller than that of mpAββ, the effect of the magnetic stirring treatment on npAββ was also examined. Figure S6a shows the capability of the MSB stirring to readily capture npAββ (20 µM) into larger aggregates at a speed of 2500 rpm over 20 min. The extent of aggregation in terms of the detected total signal area closely correlating to the concentration of MSB employed for magnetic stirring was also observed (Figure S6b).

The effects of structural transformation from oAβ42 to mpAβ42 by magnetic stirring treatment on neuron cells (N2a) was investigated in terms of cell viability, cell morphology, and cell-specific protein expression. First, the in vitro cytotoxicity of mpAβ42 induced by the rapid capture of oAβ42 species against N2a cells was evaluated using MTT and trypan blue assays. In the absence of oAβ42, MSBs (144 µg mL⁻¹) without or with magnetic stirring at 2500 rpm for 2 h resulted in negligible cell death as measured by MTT assay (Figure 5a). The cell viability was also barely affected by the stirring speed (0; 500; 1500; and 2500 rpm) and the concentration of MSB (up to 144 µg mL⁻¹) employed for the rapid oAβ42 capture in the culture medium (Figure S7). By contrast, with those cells being exposed to oAβ42 without the stirring treatment, the cell viability was significantly reduced compared to the cell only control. This result is consistent with those reported previously that oAβ42 species are responsible in large measure for neuron toxicity in AD [45–48]. Nevertheless, an essentially full retention of the viability of N2a cells incubated with oAβ42 was observed when the N2a/oAβ42 suspension was concomitantly treated with the MSB stirring. The greatly reduced cytotoxicity is ascribed to the rapid capture of the oAβ42 into large aggregates by which the Aβ42 structure is appreciably altered and their entry into N2a cells extremely limited. The cytotoxicity of oAβ42 against N2a cells via the MSB stirring treatment was also evaluated by the trypan blue staining as a measure of cell apoptosis. As shown in Figure 5b, the cytotoxicity of oAβ42 was appreciably reduced as these toxic species were captured and converted into large magnetic aggregates. Figure 5c illustrates that the LDH release from N2a cells caused by oAβ42 is greatly reduced by the magnetic stirring treatment in comparison with the run without the treatment. Apparently, the cytotoxicity of oAβ42 species was considerably alleviated by their magnetic capture into large aggregates, thereby leading to the significant reduction of cellular uptake of oAβ42 by N2a cells for neurotoxicity attenuation. Figure 5d demonstrates the comparable neuron-specific protein expression of N2a cells in the presence of oAβ42 subjected to magnetic stirring to the positive control. In contrast, the neuron specific protein expression was significantly suppressed for the run without the capture of oAβ42 species into large aggregates of oAβ42/MSBs. Note that the proteins chosen for study include MAP2 and NF-M. Finally, further supporting evidence was provided.
by the neurite morphology. As shown in Figure S8, the morphology of N2a cells, in particular the neurites (axons and dendrites), was well preserved when they were treated by oAβ42 in virtue of the superior capture effect of magnetic stirring. The neurite length of N2a cells (ca. 20 μm) in the magnetic stirring-treated group was well retained as comparable to the positive control without oAβ42. By contrast, the length of neurites was reduced to ca. 3 μm with the cells being treated with oAβ42 only. All these results strongly suggest that the MSB stirring treatment is highly capable of capturing toxic oAβ42 species and, consequently, reducing their toxicity against neuronal cells. As a result, rather high cell integrity and viability are achieved.

**Figure 5.** Effective therapeutic action by capture of oAβ42 under magnetic stirring with MSBs. (a) In vitro cytotoxicity of N2a cells with or without magnetic stirring treatment by MTT and (b) trypan blue assays. The experiment was independently repeated three times. Error bars show standard deviations. (c) LDH release from N2a cells with and without the oAβ42 capture by the MSB stirring treatment. (d) Effects of oAβ42 on neuron-specific protein expression (MAP2 and NF-M) with and without the magnetic stirring treatment (n = 6). Cell nuclei were stained with Hoechst 33342 (λex = 405 nm, λem = 450–500 nm), microtubules with MAP2 marker (λex = 495 nm, λem = 500–550 nm) and neurofilaments with NF-M marker (λex = 633 nm, λem = 640–660 nm). Scale bar: 50 μm. ***p < 0.005 and N.S. p > 0.05. Error bars represent mean ± s.d. (n = 8).

### 3.3. Functionality of N2a Cells and Phagocytic Action of BV-2 Cells

The cellular functions in terms of specific protein expression after the rapid oAβ42 capture treatment on neuron cells were examined by western blotting. Figure 6 demonstrates that the MAP2 proteins, the NF-M protein, and NeuN were found normally expressed from N2a cells with a negligible effect of oAβ42 under magnetic stirring. On the other hand, the specific protein expression was significantly reduced in the negative control by oAβ42 without magnetic stirring. The quantification of the specific protein expression is also shown in Figure 6. Moreover, in the presence of npAβ42 instead of oAβ42, the specific expression of MAP2a, MAP2b, MAP2c, or NF-M on N2a cells was comparable to the blank control. This signifies that the neurotoxicity of both npAβ42 and mpAβ42 against N2a cells is substantially reduced compared to oAβ42 (Figure S9). In excellent agreement with the data obtained from the cell viability and morphology (Figure 5 and Figure S8), these results strongly imply that the effective therapeutic action is indeed achieved by capture of oAβ42 via MSBs under rotating magnetic field.
Figure 6. Neuron-specific protein expression of N2a cells receiving the magnetic stirring treatment. 
(a) Effects of oAβ42 on protein expression (MAP2a/MAP2b, MAP2c, NF-M, and NeuN) with and without the magnetic stirring (n = 3). β-actin was used as the loading control. The oAβ42 concentration was 160 μM. (b) The relative intensities of neuron-specific protein expression of N2a cells receiving magnetic stirring with MSBs were included.

As illustrated in Figure 7 and Figure S10, BV-2 cells (as a microglial cell model) treated with oAβ42 species exhibited quite weak fluorescence signals from Triton X-100 facilitated intracellular IHC staining using 6E10 as the primary antibody. In contrast, the fluorescence signal intensity was greatly enhanced for the cells treated with either npAβ42 or mpAβ42. This is most likely due to the enhanced uptake of mpAβ42 (or npAβ42) aggregates with activating the toll-like receptor (TLR)-associated endocytosis [49–52]. It was reported that the interactions of TLR-4 with CD14 on cell membranes were enhanced through the activation of CD14 upon their binding with Aβ42 species, triggering the TLR/CD14-mediated endocytosis [53]. On the other hand, the enhanced uptake of mpAβ42 by BV-2 cells compared to npAβ42 (Figure 7) is presumably caused by their enlarged size that inevitably increases
contacts with CD14 on the cell membrane, thereby facilitating the TLR-mediated phagocytosis. It has been recognized that the internalization of $\alpha$-$\beta_{42}$ species by microglia induces the M1 phenotype polarization of the cells, known for the reduced phagocytic activity toward neurotoxic species [54]. This will then lead to an increase in neuron apoptosis.

Figure 7. Phagocytic action of BV-2 cells. (a) Laser scanning confocal microscope (LSCM) images of BV-2 cells after co-incubation with $\alpha$-$\beta_{42}$, npA$\beta_{42}$, and mpA$\beta_{42}$, respectively ($n = 8$). A$\beta_{42}$ in different forms was IHC stained using 6E10 as the primary antibody ($\lambda_{ex} = 565$ nm, $\lambda_{em} = 680–730$ nm). Scale bar: 50 µm. (b) Relative uptake index of A$\beta_{42}$ by BV-2 cells. One-way ANOVA was used to examine the mean differences between the end points of the data groups. **$p < 0.01$. Error bars represent mean ± s.d. ($n = 8$).

As shown in Figure 8a,b, the production of the pro-inflammatory cytokines such as IL-1β and TNF-α from microglial cells after uptake of mpA$\beta_{42}$ (or npA$\beta_{42}$) was substantially reduced as compared to the uptake of $\alpha$A$\beta_{42}$. This is also reflected by a significant increase in secretion of IL-10 (an anti-inflammatory cytokine) from microglial cells co-incubated with mpA$\beta_{42}$ (or npA$\beta_{42}$) aggregates as compared to $\alpha$A$\beta_{42}$ species (Figure 8c). Comparing the differences in the levels of both pro-inflammatory cytokines and anti-inflammatory cytokines from microglia treated with mpA$\beta_{42}$ species and plaques (mpA$\beta_{42}$ and npA$\beta_{42}$), respectively, the extent of the $\alpha$A$\beta_{42}$-induced polarization of microglia to M1 type was reduced for the run with $\alpha$A$\beta_{42}$ being captured and transformed into mpA$\beta_{42}$ (or npA$\beta_{42}$) via the magnetic stirring treatment. With the decreased pro-inflammatory cytokines and the increased anti-inflammatory cytokines, the neuroinflammation as one of the AD causes is thus greatly reduced. As shown in Figure S11, a significant difference in the viability of N2a cells after 24 h incubation in conditioned media collected separately from the co-incubations of BV-2 cells with $\alpha$A$\beta_{42}$ and those with mpA$\beta_{42}$ was observed. Owing to the reduced inflammatory responses, the viability of the neuron cells in conditioned medium from the co-incubation of BV-2 cells with the stirring-induced A$\beta_{42}$ aggregates was thus promoted. These data strongly imply that the magnetic stirring treatment is capable of effectively reducing neuroinflammation, thereby leading to a pronounced increase in the survival of N2a cells. In addition, the preliminary in vivo study showed no obvious tissue damage with the brain receiving the MSB stirring treatment (Figure S12a). The MSBs were mostly degraded over 15 days after the intrahippocampal injection (Figure S12b). No significant increases in cell apoptosis and ROS generation were found from the staining of the brain tissues with
caspase 3 marker and with SOSG in the treated mice compared to the control group (Figure S12c). These results further demonstrated the safety and feasibility of this novel approach in practical applications for the AD treatment.

Figure 8. Cytokine secretion from BV-2 cells treated with αAβ42, mpAβ42, and npAβ42, respectively, for 6 h. Concentrations of IL-1β (a), TNF-α (b), and IL-10 (c) were determined in triplicate wells by ELISA analyses. The experiments were independently repeated three times and one-way ANOVA was used to examine the mean differences between the data groups. *** p < 0.005, ** p < 0.01, * p < 0.05, and N.S. p > 0.05. Error bars represent mean ± s.d. (n = 3).

4. Conclusions

In this work, we have demonstrated the successful development of the MSB-stirring based AD therapy system for rapid effective capture of αAβ42 species that are subsequently transformed into large magnetic aggregates (mpAβ42) in vitro. In this manner, the neurotoxicity of αAβ42 against neuronal cells and the αAβ42-induced polarization of microglia to M1 type characterized by high pro-inflammatory propensity can be significantly reduced. Through the increased close contact among αAβ42 species by stirring and magnetic attraction of MSB-entrapped αAβ42 aggregates under rotating magnetic field, rapid effective conversion of neurotoxic αAβ42 species into harmless mpAβ42 can be achieved. The MSB therapy system not only exhibits negligible cytotoxicity toward neuronal cells in the absence or presence of rotating magnetic field, but also greatly reduces the neurotoxicity of αAβ42 by rapid capture of αAβ42 species into mpAβ42 aggregates even with a concentration at 0.3 μM. The magnetic stirring treatment has shown a superior capability of maintaining the functionality of N2a cells in viability, specific protein expression and neurite outgrowth, and reducing the levels of pro-inflammatory cytokines secreted from M1 type microglial cells due to the effective agglutination of toxic αAβ42 species into mpAβ42. With the limited polarization of microglia into M1 type, the effective clearance of mpAβ42 via the phagocytosis of microglia was achieved. The brain tissue histologic study showed no obvious tissue damage with the mice receiving the MSB stirring treatment in the hippocampus area. Neither cell apoptosis nor ROS generation in the brain tissues were found to be significantly increased. The MSBs were extensively degraded over 15 days after the intracranial injection. These results strongly suggest that the magnetic stirring treatment with MSBs be a promising strategy for improving the AD treatment. Further detailed studies concerning the in vivo therapeutic efficacy of the MSB stirring treatment against AD is in progress.

Supplementary Materials: The following are available online at http://www.mdpi.com/2079-4991/10/7/1284/s1. Figure S1: Characterization of SPIONs. (a) TEM image of OA-SPIONs and (b) TEM image of LA/OA-SPIONs. Scale bar: 50 nm. (c) TGA measurement of OA-SPIONs. (d) Field-dependent magnetic curves of OA-SPIONs (black line) and LA/OA-SPIONs (red line) measured at the same Fe concentration. (e) XRD patterns of OA-SPIONs and LA/OA-SPIONs. Figure S2: Alignment of MSBs examined by optical microscopy. (a) The random localization of MSBs in the absence of external magnet. (b) Uniform alignment of MSBs in accordance to the magnet (black arrows). (c) Dispersion of rhodamine B in water droplets by magnetic stirring with MSBs under rotating magnetic field. Figure S3: Colloidal stability over 120 min in different aqueous milieu. Count rates of MSBs in DI water (—), DMEM (—), DMEM containing 10% FBS (—) and FBS (—) at different time intervals with various magnetic stirring speeds: (a) 0, (b) 500, (c) 1500 and (d) 2500 rpm. Error bars represent mean ± s.d. (n = 6). Figure S4:
 Pronounced effect of capturing αβ42 by magnetic stirring (2500 rpm) with MSBs (144 µg/mL) into aggregates was observed by LSCM (n = 10). The αβ42 was stained with ThT and CR. Scale bar: 100 µm. Figure S5: Detailed structural characterizations of npαβ42. (a) Fluorescence intensity of ThT in aqueous solution of αβ42 (20 µM) as a function of time. (b) CR absorption spectra (420-580 nm) of αβ42 (20 µM) with different incubation time intervals.

(c) TEM and HR-TEM images of αβ42. (d) TEM and HR-TEM images of npαβ42. Figure S6: Capture of npαβ42 into large aggregates by MSB stirring (n = 10). (a) Fluorescence images of npαβ42 treated with magnetic stirring as a function of the concentration of MSBs at 2500 rpm for 20 min. The αβ42 concentration was 20 µM. The npαβ42 was attained from incubation of αβ42 in PBS under mild shaking at 37 °C for 7 days. Scale bar: 100 µm. (b) Total signal areas of large aggregates by ThT and CR staining. *** p < 0.005, ** p < 0.01, * p < 0.05 and N.S. p > 0.05. Error bars represent mean ± s.d. (n = 10). Figure S7: (a) LSCM images of the neuron (N2a) outgrowth with magnetic stirring of various speeds for 2 h (MSB 144 µg mL⁻¹). Cytoskeleton was stained with F-actin marker. Scale bar: 100 µm. The viability of N2a cells receiving the magnetic stirring treatment with MSBs (144 µg mL⁻¹) at various stirring speeds. (b) Cell viability of N2a cells after the capture of αβ42 by magnetic stirring with MSBs of different concentrations at 2500 rpm for preset time intervals. The cell viability was evaluated by MTT assay. Error bars represent mean ± s.d. (n = 6). Figure S8: Representative LSCM images of N2a cells before and after the magnetic stirring treatment. LSCM images of N2a cells treated with either αβ42 only or αβ42/MSBs (αβ42 concentration: 160 µM; MSB 144 µg mL⁻¹) with and without magnetic stirring (2500 rpm) for 2 h (n = 6). The cell nuclei and cytoskeleton were stained with Hoechst 33342 and F-actin marker, respectively. Scale bar: 50 µm. Quantitative data of neurite length (µm) and number with and without magnetic stirring treatment are also included. *** p < 0.005. Error bars represent mean ± s.d. (n = 6). Figure S9: Neuron-specific protein expression of N2a cells treated either with αβ42 or mpαβ42 (n = 3). (a) Effects of npαβ42 and mpαβ42 on neuron-specific protein expression (MAP2a/MAP2b, MAP2c, NF-M and NeuN). β-actin was used as the loading control. (b) Relative signal intensities of individual neuron-specific proteins from N2a cells after the npαβ42 or mpαβ42 treatment. The αβ42 concentration was 160 µM. * p < 0.05. Error bars represent mean ± s.d. (n = 3). Figure S10: Phagocytic actions of BV-2 cells toward αβ42, npαβ42 and mpαβ42. Representative LSCM images of the αβ42 uptake by BV-2 cells (n = 8). αβ42 in different forms was IHC-stained using 6E10 as the primary antibody (λex = 565 nm, λem = 680–730 nm). Cell nuclei and cytoskeleton were stained with Hoechst 33342 and F-actin marker, respectively. Scale bar: 50 µm. Figure S11: Cell viability of N2a cells after 24 h-incubation in conditioned media collected separately from the co-incubations of BV-2 cells with αβ42 and BV-2 cells with mpαβ42. *** p < 0.005, ** p < 0.01. Error bars represent mean ± s.d. (n = 6). Figure S12: Brain tissue examination with (a) H&E (b) prussian blue (MSBs) and (c) DAPI (nuclei), SOSG (ROS) and caspase-3 (cell apoptosis) IHC staining from healthy C57BL/6J mice receiving MSB stirring treatment (2400 rpm, 20 min) (n = 3). Scale bars for (a) and (b): 500 µm. Scale bar for (c): 100 µm. Table S1: Characterization of OA-SPIONs and LA/OA-SPIONs by DLS. Video S1: Magnetic stirring of MSBs recorded by charged-coupled device (CCD) video camera. Video S2: The blinking phenomenon caused by light scattering with MSB stirring recorded by charged-coupled device (CCD) video camera.

Author Contributions: Y.-C.T., J.-C.L., T.-I.L., and H.-C.C. conceived and designed the experiments. C.-Y.C. provided the materials and coordinated the western blotting study. J.-C.L. prepared the materials and carried out the experiments. Y.-C.T., C.-S.C., and H.-C.C. co-wrote the manuscript. M.-Y.S. and I.-L.L. participated data analyses and discussion. All authors discussed the results and commented on the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work is supported by the Ministry of Science and Technology, Taiwan (MOST 108-2314-B-007-004-MY3 and MOST 107-2221-E-007-032-MY3); the National Tsing Hua University (109-25201E); Hsinchu Mackay Memorial Hospital, Taiwan (M5HTTH-TH10905); and China Medical University Hsinchu Hospital (CMUHCH-DMR-109-006), Taiwan.

Conflicts of Interest: The authors declare no competing interests.

References
1. Klein, W.L.; Krafft, G.A.; Finch, C.E. Targeting small Abeta oligomers: The solution to an Alzheimer’s disease conundrum? Trends Neurosci. 2001, 24, 219–224. [CrossRef] [PubMed]
2. Maia, M.A.; Sousa, E. BACE-1 and γ-secretase as therapeutic targets for Alzheimer’s disease. Pharmaceuticals 2019, 12, 41. [CrossRef] [PubMed] [PubMed]
3. Cummings, J.; Lee, G.; Ritter, A.; Sabbagh, M.; Zhong, K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement. 2019, 5, 272–293. [CrossRef] [PubMed]
4. Panza, F.; Lozupone, M.; Logroscino, G.; Ibimbo, B.P. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 2019, 15, 73–88. [CrossRef] [PubMed] [PubMed]
5. Doody, R.S.; Thomas, R.G.; Farlow, M.; Ivatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; Raman, R.; Sun, X.; Aisen, P.S. Phase 3 trials of Solanezumab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 2014, 370, 311–321. [CrossRef] [PubMed]
6. Lauren, J.; Gimbel, D.A.; Nygaard, H.B.; Gilbert, J.W.; Strittmatter, S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. *Nature* **2009**, *457*, 1128–1132. [CrossRef] [PubMed]

7. Zhang, Y.; Zhao, Y.; Zhang, L.; Yu, W.; Wang, Y.; Chang, W. Cellular prion protein as a receptor of toxic amyloid-β42 oligomers is important for Alzheimer’s disease. *Front. Cell. Neurosci.* **2019**, *13*, 339. [CrossRef]

8. EI-Shimy, I.A.; Heikal, O.A.; Hamdi, N. Minocycline attenuates Aβ oligomers-induced pro-inflammatory phenotype in primary microglia while enhancing Aβ fibrils phagocytosis. *Neurosci. Lett.* **2015**, *609*, 36–41. [CrossRef]

9. Cherry, J.D.; Olschowka, J.A.; O’Banion, M.K. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. *J. Neuroinflamm.* **2014**, *11*, 98. [CrossRef]

10. Block, M.L.; Hong, J.S. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. *Prog. Neurobiol.* **2005**, *76*, 77–98. [CrossRef]

11. Tobinick, E.L.; Gross, H. Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. *J. Neuroinflamm.* **2008**, *5*, 2. [CrossRef] [PubMed]

12. De Felice, F.G.; Ferreira, S.T. Inflammation, defective insulin signalling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. *Diabetes* **2014**, *63*, 2262–2272. [CrossRef] [PubMed]

13. Lee, C.Y.; Landreth, G.E. The role of microglia in amyloid clearance from the AD brain. *J. Neural Transm.* **2010**, *117*, 949–960. [CrossRef]

14. Yang, W.; Wu, Q.; Yuan, C.; Gao, J.; Xiao, M.; Gu, M.; Ding, J.; Hu, G. Aquaporin-4 mediates astrocyte response to β-amyloid. *Cell. Neurosci.* **2012**, *49*, 406–414. [CrossRef] [PubMed]

15. Kanekiyo, T.; Cirrito, J.R.; Liu, C.C.; Shihohara, M.; Li, J.; Schuler, D.R.; Shihohara, M.; Holtzman, D.M.; Bu, G. Neuronal clearance of amyloid-β by endocytic receptor LRP1. *J. Neurosci.* **2013**, *33*, 19276–19283. [CrossRef]

16. Tang, Y.; Le, W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. *Mol. Neurobiol.* **2016**, *53*, 1181–1194. [CrossRef]

17. Winkler, E.; Julius, A.; Steiner, H.; Langosch, D. Homodimerization protects the amyloid precursor protein C99 fragment from cleavage by γ-secretase. *Biochemistry* **2015**, *54*, 6149–6152. [CrossRef]

18. Parajuli, B.; Sonobe, Y.; Horituchi, H.; Takeuchi, H.; Mizuno, T.; Suzumura, A. Oligomeric amyloid β induces IL-1β processing via production of ROS: Implication in Alzheimer’s disease. *Cell Death Dis.* **2013**, *4*, e975. [CrossRef]

19. Prade, E.; Barucker, C.; Sarkar, R.; Althoff-Ospelt, G.; Lopez del Amo, J.M.; Hossain, S.; Zhong, Y.; Multhaup, G.; Reif, B. Sulindac sulfide induces the formation of large oligomeric aggregates of the Alzheimer’s disease amyloid-β peptide which exhibit reduced neurotoxicity. *Biochemistry* **2016**, *55*, 1839–1849. [CrossRef]

20. Bieschke, J.; Herbst, M.; Wiglenda, T.; Friedrich, R.P.; Boeddriich, A.; Schiele, F.; Kleeckers, D.; Lopez del Amo, J.M.; Gruening, B.A.; Wang, Q.; et al. Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils. *Nat. Chem. Biol.* **2011**, *8*, 93–101. [CrossRef]

21. Keskin, A.D.; Kekus, M.; Adelsberger, H.; Neumann, U.; Shimshek, D.R.; Song, B.; Zott, B.; Peng, T.; Forstl, H.; Staufenbiel, M.; et al. BACE inhibition-dependent repair of Alzheimer’s pathophysiology. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 8631–8636. [CrossRef] [PubMed]

22. Meier, S.R.; Syvanen, S.; Hultgqvist, G.; Fang, X.T.; Roshanbin, S.; Lannfelt, L.; Neumann, U.; Sehlin, D. Antibody-based in vivo PET imaging detects amyloid-β reduction in Alzheimer transgenic mice after BACE-1 inhibition. *J. Nucl. Med.* **2018**, *59*, 1885–1891. [CrossRef] [PubMed]

23. Huang, W.C.; Lu, I.L.; Chiang, W.H.; Lin, Y.W.; Tsai, Y.C.; Chen, H.H.; Chang, C.W.; Chiang, C.S.; Chiu, H.C. Tumortrophic adipose-derived stem cells carrying smart nanotherapeutics for targeted delivery and dual-modality therapy of orthotopic glioblastoma. *J. Control Release* **2017**, *254*, 119–130. [CrossRef]

24. Hu, Y.; He, L.; Yin, Y. Magnetically responsive photonic nanochains. *Angew. Chem. Int. Ed. Engl.* **2011**, *50*, 3747–3750. [CrossRef]

25. Dahlgren, K.N.; Manelli, A.M.; Stine, W.B.; Jr.; Baker, L.K.; Krafft, G.A.; DaLu, M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. *J. Biol. Chem.* **2002**, *277*, 32046–32053. [CrossRef] [PubMed]

26. Lambert, M.P.; Viola, K.L.; Chang, L.; Morgan, T.E.; Yu, J.; Venton, D.L.; Krafft, G.A.; Finch, C.E.; Klein, W.L. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. *J. Neurochem.* **2001**, *79*, 595–605. [CrossRef]
27. Kuznetsova, I.M.; Sulatskaya, A.I.; Uversky, V.N.; Turoverov, K.K. Analyzing thioflavin T binding to amyloid fibrils by an equilibrium microdialysis-based technique. *PLoS ONE* **2012**, *7*, e30724. [CrossRef]

28. Hudson, S.A.; Ecroyd, H.; Kee, T.W.; Carver, J.A. The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. *FEBS J.* **2009**, *276*, 5960–5972. [CrossRef]

29. Huang, C.; Xu, D.; Zhang, K.; Shentu, J.; Yan, S.; Wu, D.; Wang, Q.; Cui, W. A11-positive β-amyloid oligomer preparation and assessment using dot blotting analysis. *J. Vis. Exp.* **2018**, *135*, 57592.

30. Xue, C.; Tran, J.; Wang, H.; Park, G.; Hsu, F.; Guo, Z. Aβ42 fibril formation from predominantly oligomeric samples suggests a link between oligomer heterogeneity and fibril polymorphism. *R. Soc. Open Sci.* **2019**, *6*, 190179. [CrossRef]

31. Chowdhury, S.R.; Mondal, S.; Muthuraj, B.; Balaji, S.N.; Trivedi, V.; Iyer, P.K. Remarkably efficient blood-brain barrier crossing polyfluorene-chitosan nanoparticle selectively tweaks amyloid oligomer in cerebrospinal fluid and Aβ1–40. *ACS Omega* **2018**, *3*, 8059–8066. [CrossRef] [PubMed]

32. Sun, L.; Zhong, Y.; Gui, J.; Wang, X.; Zhuang, X.; Weng, J. A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers. *Int. J. Nanomed.* **2018**, *13*, 843–856. [CrossRef] [PubMed]

33. Fischer, D.; Li, Y.; Ahlemeyer, B.; Krieglstein, J.; Kissel, T. In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis. *Biomaterials* **2003**, *24*, 1121–1131. [CrossRef]

34. Wang, W.; Hou, T.T.; Jia, L.F.; Wu, Q.Q.; Quan, M.N.; Jia, J.P. Toxic amyloid-β oligomers induced self-replication in astrocytes triggering neuronal injury. *EBiomedicine* **2019**, *42*, 174–187. [CrossRef] [PubMed]

35. Chakraborty, P.; Tianbai, L.; Herring, A.; Ceballos-Diaz, C.; Das, P.; Golde, T.E. Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. *Mol. Neurodegener.* **2012**, *7*, 36. [CrossRef] [PubMed]

36. Jean, Y.Y.; Baleriola, J.; Fa, M.; Hengst, U.; Troy, C.M. Stereotaxic infusion of oligomeric amyloid-beta into the mouse hippocampus. *J. Vis. Exp.* **2015**, *100*, e52805. [CrossRef]

37. Chong, W.H.; Chin, L.K.; Tan, R.L.; Wang, H.; Liu, A.Q.; Chen, H. Stirring in suspension: Nanometer-sized magnetic stir bars. *Angew. Chem. Int. Ed. Engl.* **2013**, *33*, 8570–8573. [CrossRef]

38. Malvindi, M.A.; De Matteis, V.; Galeone, A.; Brunetti, V.; Anyfantis, G.C.; Athanassiou, A.; Cingolani, R.; Pompa, P.P. Toxicity assessment of silica coated iron oxide nanoparticles and biocompatibility improvement by surface engineering. *PLoS ONE* **2014**, *9*, e85835. [CrossRef]

39. Younan, N.D.; Viles, J.H. A comparison of three fluorophores for the detection of amyloid fibers and prefibrillar oligomeric assemblies. ThT (Thioflavin T); ANS (1-Anilinonaphthalene-8-sulfonic Acid); and bisANS (4,4'-Dianilino-1,1'-binaphthyl-5,5'-disulfonic Acid). *Biochemistry* **2015**, *54*, 4297–4306. [CrossRef]

40. Biancalana, M.; Koide, S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. *Biochim. Biophys. Acta* **2010**, *1804*, 1405–1412. [CrossRef]

41. Stsiapura, V.I.; Maskevich, A.A.; Kuzmitsky, V.A.; Turoverov, K.K.; Kuznetsova, I.M. Computational study of thioflavin T torsional relaxation in the excited state. *J. Phys. Chem. A* **2007**, *111*, 4829–4835. [CrossRef] [PubMed]

42. Younan, N.D.; Viles, J.H. A comparison of three fluorophores for the detection of amyloid fibers and prefibrillar oligomeric assemblies. ThT (Thioflavin T); ANS (1-Anilinonaphthalene-8-sulfonic Acid); and bisANS (4,4'-Dianilino-1,1'-binaphthyl-5,5'-disulfonic Acid). *Biochemistry* **2015**, *54*, 4297–4306. [CrossRef]

43. Frid, P.; Anisimov, S.V.; Popovic, N. Congo red and protein aggregation in neurodegenerative diseases. *Brain Res. Rev.* **2007**, *53*, 135–160. [CrossRef] [PubMed]

44. Meehan, S.; Berry, Y.; Luisi, B.; Dobson, C.M.; Carver, J.A.; MacPhee, C.E. Amyloid fibril formation by lens crystallin proteins and its implications for cataract formation. *J. Biol. Chem.* **2004**, *279*, 3413–3419. [CrossRef] [PubMed]

45. Sengupta, U.; Nilson, A.N.; Kayed, R. The Role of amyloid-β oligomers in toxicity, propagation, and immunotherapy. *EBioMedicine* **2016**, *6*, 42–49. [CrossRef] [PubMed]

46. Kayed, R.; Lasagna-Reeves, C.A. Molecular mechanisms of amyloid oligomers toxicity. *J. Alzheimers Dis.* **2013**, *33*, 67–78. [CrossRef]

47. Kumar, S.; Wirths, O.; Stuber, K.; Wunderlich, P.; Koch, P.; Theil, S.; Rezaei-Ghaleh, N.; Zweckstetter, M.; Bayer, T.A.; Brustle, O.; et al. Walter. Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. *Acta Neuropathol.* **2016**, *131*, 525–537. [CrossRef]

48. Benilova, I.; Karran, E.; De Strooper, B. The toxic Aβ oligomer and Alzheimer’s disease: An emperor in need of clothes. *Nat. Neurosci.* **2012**, *15*, 349–357. [CrossRef]
49. Doi, Y.; Mizuno, T.; Maki, Y.; Jin, S.; Mizoguchi, H.; Ikeyama, M.; Doi, M.; Michikawa, M.; Takeuchi, H.; Suzumura, A. Microglia activated with the toll-like receptor 9 ligand CpG attenuate oligomeric amyloid [beta] neurotoxicity in in vitro and in vivo models of Alzheimer’s disease. *Am. J. Pathol.* 2009, 5, 2121–2132. [CrossRef]

50. Suzumura, A. Neurotoxicity by microglia: The mechanisms and potential therapeutic strategy. *Fukuoka Igaku Zasshi* 2009, 1, 243–247.

51. Richard, K.L.; Filali, M.; Prefontaine, P.; Rivest, S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1–42 and delay the cognitive decline in a mouse model of Alzheimer’s disease. *J. Neurosci.* 2008, 28, 5784–5793. [CrossRef] [PubMed]

52. Tahara, K.; Kim, H.D.; Jin, J.J.; Maxwell, J.A.; Li, L.; Fukuchi, K. Role of toll-like receptor signalling in Aβ uptake and clearance. *Brain* 2006, 129, 3006–3019. [CrossRef] [PubMed]

53. Fujikura, M.; Iwahara, N.; Hisahara, S.; Kawamata, J.; Matsumura, A.; Yokokawa, K.; Saito, T.; Manabe, T.; Matsushita, T.; Suzuki, S.; et al. CD14 and toll-like receptor 4 promote fibrillar Aβ42 uptake by microglia through a clathrin-mediated pathway. *J. Alzheimers Dis.* 2019, 68, 323–337. [CrossRef] [PubMed]

54. Geloso, M.C.; Corvino, V.; Marchese, E.; Serrano, A.; Michetti, F.; D’Ambrosi, N. The dual role of microglia in ALS: Mechanisms and therapeutic approaches. *Front. Aging Neurosci.* 2017, 9, 242. [CrossRef]